An antiarrhythmic drug, amiodarone, contains 37% iodine by weight and is structurally similar to the thyroid hormones. The drug inhibits hepatic 5'-deiodinase, resulting in increases in serum thyroxin and "reverse" tniodothyronine, whereas the concentration of tniodothyronine in serum is decreased. There is a significant incidence of either hypothyroidism or hyperthyroidism in patients who are being treated with the drug. This is largely the effect of iodine released from the drug during chronic therapy, but in susceptible individuals amiodarone may unmask autoimmune thyroid disease. much as 18 mg of iodine per day may be released from the drug. This is considerably in excess of the average daily intake of dietary iodine, which seldom exceeds 700 g and is usually <200 g per day (6). Ainiodarone therapy thus presents a considerable iodine load to the thyroid.
Some effects of the drugsuggestthat it may interferewiththe action of thyroidhormones at the cellular level, inducinga state of localized hypothyroidism.
Amiodarone is a drug with unique pharmacological and electrophysiological
properties.
It has complex effects on peripheral iodothyronine metabolism and, because of iodine released during chronic therapy, it also may affect the function of the thyroid gland directly. The drug is effective in a wide range of cardiac rhythm disturbances, including those refractory to the traditional agents, and it exerts a significant anti-anginal action, lacking the hemodynainic disadvantages of other antiarrhythmic drugs. The use of amiodarone is increasing, especially in nonspecialist centers. The mechanism of the interaction of the drug with the thyroid is not widely understood, but changes in practice mandate that both clinician and clinical biochemist be able to assess thyroid status in patients taking amiodarone. much as 18 mg of iodine per day may be released from the drug. This is considerably in excess of the average daily intake of dietary iodine, which seldom exceeds 700 g and is usually <200 g per day (6). Ainiodarone therapy thus presents a considerable iodine load to the thyroid.
Elimination of the drug is biphasic, with an initial rapid phase followed by a prolonged period of slow elimination; significant concentrations of the drug remain detectable many weeks after cessation of therapy (7) .
Although generally well tolerated, the drug has been associated with a wide spectrum of side effects: dermatological, ocular, neuromuscular, hepatic, and pulmonary. A photosensitive skin rash is the most common troublesome adverse effect of the drug, whereas corneal microdeposits of the drug, although they occur in most patients, do not usually give rise to symptoms. Neuromuscular reactions are usually mild, but symptomatic peripheral neuropathy may occur. Changes in hepatic enzymes occur in up to 20% of patients, although frank liver disease is a relatively rare complication of therapy with amiodarone.
Pulmonary fibrosis, a severe and life-threatening complication, fortunately is extremely rare (8) . The drug almost invariably affects results of thyroid-function tests and is associated with an appreciable incidence of frank thyroid dysfunction.
Abnormalities
of thyroid function may occur for the first time or continue after amiodarone treatment has been stopped, owing to the extremely slow elimination of the drug.
Thyroid-Function Tests
Biochemical changes during therapy with amiodarone are common (Table 1 ) but usually not clinically significant. Increases in plasma thyroxin (T4) with the drug have been long recognized and confirmed in a number of studies (9) (10) (11) (12) (13) . This increase in T4 parallels the decrease in heart rate induced by the drug (14). Neither the concentrations of thyroid-hormone-binding proteins nor the binding of iodo- 10, 12 ). The concentration of plasma "reverse" T3 is consistently increased during amiodarone therapy (10, 12, 13). These changes in thyroid hormones may take some weeks to develop, but tend to persist throughout treatment with the drug. Plasma rT3 concentrations may relate to the clinical effects of amiodarone, with satisfactory rhythm control usually apparent at 500-1000 ng/L (normal <500 ngIL), whereas adverse effects are associated with rT3 concentrations >1000 ngJL (17) . Thus, measurement of rT3 may be a convenient alternative to monitoring concentrations of the drug itself. The pattern of changes in iodothyronines with amiodarone is attributable to inhibition of hepatic 5'-deiodinase and resembles that after use of roentgenographic contrast media such as iopanoic acid, which also produce a transient increase in TSH (18). The increase in TSH with amiodarone treatment (10, 13, 19) usually occurs only during the first few weeks of treatment. Concomitantly, the response of TSH to thyroliberin may be exaggerated. It is not clear whether this change in TSH secretion results from the lower T4 concentration present or from a direct action of the drug on the thyrotroph cells of the pituitary.
In the longer term, TSH concentrations are usually within the normal range in euthyroid subjects, but decreased TSH with diminished thyroliberin response has been noted in patients with treated hypothyroidism who are taking amiodarone (20) .
lodothyronine Kinetics
The concentration of a hormone in plasma represents a balance between rates of production and metabolic clearance. The effect of amiodarone on iodothyronine kinetics has been determined by use of isotopic techniques. Lambert et al. (21) have shown increased T4 production and reduced clearance in patients during chronic oral therapy. By contrast, Hershman et al. (22) found no change in the T4 clearance after six weeks of amiodarone therapy in patients with supraventricular arrhythmias.
T3 production is inhibited by amiodarone, but clearance is not affected (21). The major source of T3 is the liver, where it is produced by outer-ring deiodination of T4 at the 5' position by "type r' deiodinase. Inhibition of this enzyme by amiodarone has been demonstrated in rat-liver homogenates (23, 24) and also in isolated hepatocytes (25 (27) used compartmental analysis to study T4 kinetics, and demonstrated that amiodarone can reduce the fractional rate ofT4 transfer between serum and the rapidly equilibrating tissue pool. Because this effect is not caused by alterations of binding proteins, as already discussed, it may reflect inhibition of the T4-transport mechanism.
There are no satisfactory human data for i'F3 kinetics and, currently, the only available information is from experiments in rabbits (28). The production of rT3 by innerring deiodination ofT4 at the 5' position occurs predominantly in extrahepatic tissues and is unaffected by amiodarone. Clearance of rT3 is initially by 5' deiodination in the liver and is inhibited by the drug.
Interaction with lodothyronines at the Cellular Level
The biologically most potent thyroid hormone is T3, which is taken up into cells by a saturable, membranereceptor mediated, energy-dependent mechanism. T3 exerts its action on the cell viaa nuclear receptor, which is a nonhistone protein tightly bound to DNA. The receptor, the product of the c-erb-A oncogene, is part of a family of regulatory gene products, which includes the steroid hormone receptors (29). The action of thyroid hormones has been studied by using pituitary cells secreting growth hormone in culture. The binding of T3 to its receptor is followed rapidly by increased formation of mRNA coding for growth hormone. The rate of transcription is proportional to the concentration of thyroid hormone receptor complexes (30). De Nayer (31) found that 85% of the iodothyronine bound to these receptors is T3.
Amiodarone may have specific effects on different tissues at the cellular level, inducing localized states of apparent thyroid imbalance. In the pituitary, TSH secretion may be increased despite high circulating concentrations of T4, suggesting a direct effect of the drug on thyrotrophs.
These cells, like others in the central nervous system, convert T4 to T by a "type II" deiodinase, distinct from the enzyme in the liver. Thyrotrophs in vivo and in vitro respond to exogenous T3, but locally produced T3 may contribute substantially to the thyroid hormone status of these cells. Type II deiodinase has a lower Km for 'F4, and is not sensitive to propylthiouracil (32 (37) (38) . Increased concentrations of rT3 decrease the amount of T3 available for feedback inhibition in the thyrotroph. It is not clear at present why the increase in TSH during arniodarone therapy is usually limited to the first few weeks of treatment. This change is not always due to observed alterations in circulating thyroid hormone concentrations, but may be due to a state of apparent hypothyroidism in the thyrotroph induced by the drug.
Selective inhibition of thyroid hormone action on the myocardium could explain some of the cardiac effects of amiodarone. Many of the effects of amiodarone on the heart resemble those seen in hypothyroidism-bradycardia, reduced myocardial oxygen consumption, decrease in tension-time index, prolongation of action-potential duration (39), and changes in myosin ATPase (23). Singh and Vaughan Williams (40) found that, in rabbits, Lugol's iodine had no effect on action-potential duration, but the effects of amiodarone were antagonized by T3 admimstration. Oral T3 has not, however, been found to antagonize the antiarrhythmic action of amiodarone in humans (41). lopanoic acid produces changes in thyroid hormones similar to those of anuodarone but has no antiarrhythmic action (42). Inhibition of deiodinase is not the only mechanism by which amiodarone may inhibit thyroid hormone action on the heart: its effect on iodothyronine uptake, 
Thyrotoxicosis
Sporadic cases of thyrotoxicosis with amiodarone have been well described but the condition has only recently been systematically studied. Estimates for the prevalence of hyperthyroidism in amiodarone-treated patients vary between 1% and 15% (49, 50) . In most cases, the thyrotoxicosis appears to be iodine-induced. Unlike spontaneous thyrotoxicosis, the condition is slightly more common in males than in females (51). Iodine in excess usually inhibits the thyroid (52), but may occasionally precipitate thyrotoxicosis, particularly in patients with pre-existing thyroid abnormalities (53, 54) such as subclinical thyroid autonomy. In a proportion of patients with iodine-induced thyrotoxicosis, no pre-existing thyroid abnormality can be identified (55). Amiodarone therapy is now the most common cause of this clinical entity. Martino et al. (56) have compared the incidence of thyroid dysfunction in an area of low iodine intake (Tuscany, Italy) with that in an iodinereplete area (Massachusetts, USA). Thyrotoxicosis was more common in Tuscany (9.6%) than in Massachusetts (2%). The incidence of amiodarone-induced hyperthyroidism is generally low in areas of iodine repletion (57-59). The condition may occur after amiodarone therapy has been withdrawn (60).
Symptoms of hyperthyroidism may be masked by the patient's condition and by the effects of amiodarone. A small, often transient, goiter may be present (55, 61, 62) , but dermopathy or ophthalmopathy of the sort found in Graves' disease is not a feature of amiodarone-induced hyperthyroidism.
Thyroid-stimulating immunoglobulins, diagnostic of Graves' disease, are not usually detected (56, 63) , suggesting that most cases are not autoimmune in origin. No single biochemical test will reliably predict thyroid dysfunction caused by amiodarone (64) , and careful clinical evaluation is necessary in each case. Concentrations of total and freethyroid hormones are increased in most cases,but the total T4 value may be within the normal range (56) and, as in iodine-induced thyrotoxicosis from other causes, the T concentration may also be normal (46, 53) . TSH is suppressed and does not respond to intravenous injection of thyroliberin. Measurement of rT3 does not help in the diagnosis or management of hyperthyroidism. Isotope tests are of no value, because uptake of iodine by the gland is suppressed (46, 56) .
Treatment of amiodarone-induced thyrotoxicosis can be difficult. If possible, the drug should be withdrawn, at least temporarily. In deciding ontherapy, one should bear in mind that this type of hyperthyroidism frequently remits spontaneously within six months (46, 65). Destructive antithyroid therapy is not, in any case, usually appropriate, because the underlying rhythm disturbance makes elective surgery undesirable, and suppression of iodide uptake by the gland precludes radio-ablation except with very high dosesof radioactivity. Thionamide drugs are less effective than in patients with spontaneous hyperthyroidism. Propylthiouracil is to be preferred to carbimazole or methimazole because of its additional peripheral action in reducing T3 production. Recently, the combination of thionamide with potassium perchlorate has been advocated (56) and may be of some benefit. Corticosteroids also reduce iodide utilization by the gland and have been shown to hasten euthyroidism in amiodarone-induced thyrotoxicosis (46, 61) .
Hypothyroidism
The dominant effect of excess iodide on normal thyroid tissue is to inhibit the synthesis and release of hormone, both in vivo (52) and in vitro (66). Hypothyroidism is a well-described complication of amiodarone therapy of autoimmunity and iodide inhibition is hard to assess and the presence of circulating autoantibodies to the thyroid is not necessarily diagnostic of an autoimmune disease. In the study by Foresti et al. (75) , antithyroid antibodies were found not to predict the development of hypothyroidism with amiodarone. Patients with Hashimoto's thyroiditis are known to be more susceptible to the inhibitory effects of iodide on the gland (76). A phase of temporary hypothyroidism is common in patients recovering from iodineinduced thyrotoxicosis, including that caused by amiodarone (46, 55) , and permanent hypothyroidism has also been reported (77) .
There are no clinical features peculiar to amiodaroneinduced hypothyroidism.
The concentrations of thyroid hormones in serum are usually decreased, although the total T4 concentration may be within the reference range.
An increase of TSH concentration after the first few weeks of therapy is strongly suggestive of developing hypothyroidism. The anticipated increase in rT3 concentration may not occur in hypothyroid patients. Treatment is with 'F4 in the usual doses and as guided by the clinical state. Amiodarone and T4 may be used concurrently.
Amiodarone and Thyroid Autoimmunity
There is controversy concerning the relationship be- Thyroid autoimmunity may be more common in patients with ischemic heart disease (85), which must be taken into account when assessing studies such as those quoted. Although some patients with amiodarone-induced hypothyroidism may have autoimmune thyroiditis, most cases of thyroid dysfunction with amiodarone do not appear to be of autoimmune origin.
Conclusion
Changes in thyroid-function tests are almost invariably found in patients taking amiodarone: total and free T4 and rT3 concentrations are increased, and T3 is modestly decreased; TSH may be increased in the early weeks of therapy. These changes are usually due to the drug's extra-thyroidal actions and do not indicate thyroid dysfunction. They should not detract from the use of amiodarone when it is clinically indicated.
There is, however, an appreciable incidence of both hyper-and hypothyroidism.
The former is more common in areas of previous iodine deficiency and is diagnosed by increased T3 values combined with suppressed TSH and absent responseto thyroliberin.
The condition is frequently
self-limiting but may be resistant to standard therapy and require the use of corticosteroids. Hypothyroidism resulting from amiodarone therapy is generally more common than hyperthyroidism and is diagnosed by decreased concentrations of thyroid hormones and elevated TSH. T4 replacement in such patients can be administered concurrently with amiodarone.
Thyroid investigations are difficult to interpret in patients taking amiodarone; each case of suspected thyroid dysfunction must be carefully assessed by an experienced clinician. Baseline thyroid hormone and TSH concentrations, and thyroid autoantibodies, should be assessed in all cases to identi1r patients with occult thyroid disease before therapy with amiodarone is commenced. Patients with a personal or family history of thyroid disease are at particular risk. Amiodarone may be used, with caution, in these at-risk groups of patients. Because of difficulties with diagnosis and treatment of thyroid disease, all patients taking amiodarone should undergo periodic evaluation (at least every six months) of thyroid status, including a clinical assessment. Only with informed and diligent monitoring can the potential hazards of amiodarone therapy be minimized.
